In a significant breakthrough, investigators at Weill Cornell Medical College and the University of California, San Francisco, have been able to overcome resistance of a form of leukemia to targeted therapy, demonstrating ...
May 24, 2011
0
0
Investigators have found that dasatinib, a drug commonly used to treat chronic myeloid leukemia, is strongly associated with kidney injury.
Sep 12, 2023
0
9
Dasatinib, a drug that often is used to treat certain types of leukemia, may have antidiabetic effects comparable to medications used to treat diabetes, and with more research may become a novel therapy for diabetic patients, ...
Nov 9, 2021
0
58
DGIST researchers have identified the causes of hypersensitivity accompanied by neurodevelopmental disorders such as autism-spectrum disorder (ASD). This is expected to make huge contributions to the early diagnosis of sensory-defective ...
Feb 14, 2020
0
40
Northwestern University and the Parkinson Study Group announced that the Nilotinib in Parkinson's Disease (NILO-PD) study showed that nilotinib, an FDA-approved treatment for chronic myelogenous leukemia being tested for ...
Dec 5, 2019
0
15
The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80 percent of people with CML who received the drug, the disease went into complete ...
Oct 16, 2019
0
1021
Most patients with chronic myelogenous leukemia can be treated with tyrosine kinase inhibitors. These drugs are highly effective and lead to deep remission and prolonged survival. Yet quiescent leukemic stem cells persist ...
Mar 21, 2019
0
6
Imagine you had a life-threatening cancer that a wonder drug had kept in remission for years. Would you risk quitting?
Mar 2, 2017
0
3
(HealthDay)—Nilotinib is associated with scurvy, possibly because of its effects on cutaneous metabolism, according to a letter to the editor published online April 28 in the Journal of Cutaneous Pathology.
May 11, 2016
0
1
University of Alabama at Birmingham researchers have found a marker on blood cells that may help the most pressing problem in chronic myelogenous leukemia, or CML, today—an inability to get patients off treatment.
Feb 16, 2016
1
58
